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Morphogenesis of the developing vascular network requires coordinated regulation of an extensive array of endothelial cell behaviors.
Precisely regulated signaling molecules such as vascular endothelial growth factor (VEGF) direct some of these endothelial behaviors. Newly
forming blood vessels also become subjected to novel biomechanical forces upon initiation of cardiac contractions. We report here the
identification of a recessive mouse mutation termed shrunken-head (shru) that disrupts function of the Titin gene. Titinwas found to be required
for the initiation of proper heart contractions as well as for maintaining the correct overall shape and orientation of individual cardiomyocytes.
Cardiac dysfunction in shrunken-head mutant embryos provided an opportunity to study the effects of lack of blood circulation on the
morphogenesis of endothelial cells. Without blood flow, differentiating endothelial cells display defects in their shapes and patterns of cell–cell
contact. These endothelial cells, without exposure to blood circulation, have an abnormal distribution within vasculogenic vessels. Further
effects of absent blood flow include abnormal spatial regulation of angiogenesis and elevated VEGF signaling. The shrunken-head mutation
has provided an in vivo model to precisely define the roles of circulation on cellular and network aspects of vascular morphogenesis.
D 2004 Elsevier Inc. All rights reserved.Keywords: Vascular development; Mouse; Heart; Genetics; Mutagenesis; ENUIntroduction
The vasculature begins to form during gastrulation, ini-
tially in extraembryonic tissues that form the yolk sac and
subsequently in the embryo itself. Shortly after gastrulation,
the heart begins to form when two bilateral fields of cardiac
precursors converge toward the midline. After fusion of these
two fields, future cardiomyocytes arrange in a single cell
layer surrounding the underlying layer of endocardium. This
linear heart tube begins to spontaneously contract by 8.5 days
post coitus (DPC) in the mouse, thereby exposing developing
endothelial cells to new biomechanical stimuli. Subsequent
growth and morphogenesis of the heart yields a rhythmically
contracting organ that circulates blood throughout the em-
bryo. After the onset of circulation, the primitive vascular
pattern is further expanded and refined by angiogenesis, the
formation of vessels through sprouting and remodeling from
existing vessels.0012-1606/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.ydbio.2004.02.006
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mechanisms that regulate cell behavior. Angioblasts use
environmental cues to migrate various distances depending
on the vessel to which they will contribute (Coffin and
Poole, 1991; Drake et al., 1998; Sugi and Markwald, 1996).
Following migration, angioblasts engage a protrusive activ-
ity of their plasma membranes whereby these cellular
extensions recognize neighboring angioblasts and form
cellular adhesions. While these cord-like cellular assemblies
are forming, primordial ECs thin, flatten, and assume the
spindle shape characteristic of differentiated ECs. Precise
regulations of protrusive activity and cellular and extracel-
lular matrix (ECM) contacts are believed to align primordial
ECs at the vertices of vascular polygons. Tensional forces
can then create a single cell-layered vascular lumen. Con-
tinued vascular fusion can combine neighboring small
caliber vessels into larger ones (Drake and Little, 1999).
These morphogenetic events are beginning to be under-
stood at the molecular level. Growth factor signaling and
communication between ECs and with the ECM are all
integrated during these cellular behaviors. Vascular endo-
thelial growth factor (VEGF) stands as a particularly im-
portant regulator of vascular morphogenesis. Several VEGF
S.R. May et al. / Developmental Biology 270 (2004) 31–4632isoforms, differing in their diffusion properties, are secreted
from a variety of cell types surrounding areas of active
vessel formation (Miquerol et al., 1999). VEGF signaling
involves two endothelial specific receptor tyrosine kinases,
Flt-1 (also known as VEGFR-1) and Flk-1 (also known as
VEGFR-2), as well as two co-receptors, neuropilin-1 and -2
((de Vries et al., 1992; Terman et al., 1992 #28; Soker et al.,
1998 #25; Gluzman-Poltorak et al., 2000)). VEGF has been
demonstrated to serve as a chemoattractant during angio-
blast migration (Cleaver and Krieg, 1998). Components of
the ECM, such as fibronectin, are also believed to provide
both supportive and instructive roles during this migration
process (Risau and Lemmon, 1988). In addition to its
described roles in EC migration and proliferation (Plouet
et al., 1989), VEGF mediates EC protrusive activity (Drake
et al., 2000) as well as vascular fusion (Drake and Little,
1995). To accommodate its variety of functions, precise
regulation of VEGF bioavailability is critical for proper
vascular development (Carmeliet et al., 1996). This regula-
tion occurs transcriptionally, posttranscriptionally, and
through VEGF’s interactions with proteins that both inhibit
(Flt-1 and SPARC) or help to activate (Flk-1 and Neuro-
pilin-1 and -2) VEGF signaling (Ferrara, 1999). Additional
investigation into the pathological alterations of VEGF
activity will undoubtedly yield new insights into how this
signaling pathway can alter vascular function in vivo.
Vasculogenesis creates lumenized vessels before circula-
tion. With the onset of heart contractions, these vessels are
subjected to new biomechanical and biochemical stimuli that
result from circulation. It has been clearly demonstrated both
in vitro and in vivo that the functional phenotype of vascular
endothelium is dynamically responsive to an array of biome-
chanical stimuli that result from circulation. Cultured endo-
thelial cells exposed to fluid shear stresses undergo a variety
of cell shape alterations. Changes in the distribution of actin-
containing stress fibers result in cultured ECs aligning with
the direction of flow and elongating their cell bodies (Dewey
et al., 1981; Frame and Sarelius, 2000). Shear stresses can
also alter the position of the microtubule organizing complex,
the Golgi apparatus, and the nucleus of ECs (Coan et al.,
1993). The number and distribution of focal adhesions
change in response to shear stress, and cultured ECs tend to
migrate away from the source of flow (Li et al., 2002). It is
noteworthy that many of these in vitro responses to shear
stress mimic aspects of vessel morphogenesis that occur in
vivo. Blood flow has been shown to direct angiogenic growth
and remodeling within the extraembryonic yolk sac (Koushik
et al., 2001; Luo et al., 2001) as well as regulate glomerular
morphogenesis within the kidney (Serluca et al., 2002).
However, it is not clear what distinct steps of vessel morpho-
genesis are affected by lack of circulation within the embryo
because vessel development has not been thoroughly studied
in mouse models immediately following primary cardiac
defects.
In this paper, we describe the localization and phenotypic
characterization of a mutation in the mouse Titin gene. Titinproteins are megadalton-sized filamentous molecules that
function as molecular springs in striated muscle (reviewed
in (Tskhovrebova and Trinick, 2002). Titin function is of
critical importance for muscle elasticity as well as structural
integrity of the sarcomere. Various mutations in Titin have
been shown to cause heart failure in the form of dilated
cardiomyopathy (Gerull et al., 2002; Xu et al., 2002) or
skeletal muscular dystrophy (Garvey et al., 2002; Hackman
et al., 2002). The shrunken-head (shru) mutation allowed us
to study Titin’s role in the development of the mouse heart.
Hearts of mutant embryos displayed weak spontaneous
contractions from the outset and never developed a strong,
regular contractile rhythm. The initiation of blood circula-
tion occurred over a day later in mutants than in wild-type
embryos. Shru hearts did not become dilated as occurs with
other characterized Titin mutations such as pickwickm171
(pikm171) (Xu et al., 2002). Instead, both the myocardial and
endocardial cells in shru hearts were misaligned. Because
the shru mutant phenotype produces weak heart contractil-
ity, this also provided an opportunity for a thorough study of
the immediate and protracted effects that lack of circulation
has on blood vessel morphogenesis. Vessel lumen mainte-
nance was disrupted and ECs were mispositioned along the
anterior–posterior (A–P) axis as part of the novel vascular
defects seen in shru embryos shortly after the delay of
circulation. Defects in endothelial shape and cell–cell con-
tacts are believed to be mechanistic causes for these specific
vessel assembly errors. Vessels then quickly developed large
dilations and underwent aberrant sprouting and pruning
indicating that angiogenesis was misregulated. Elevated
VEGF expression and a genetic interaction between shru
and Flt-1 indicated that absent circulation produced abnor-
mal VEGF signaling which likely contributed to the vascu-
lar defects in mutant embryos. In the process of
characterizing shru, a new role for Flt-1 in controlling EC
number was also identified. Analysis of the shrunken-head
mutation has defined the in vivo roles of cardiac function in
directing specific endothelial cell behaviors that elicit vas-
cular morphogenesis.Materials and methods
Mapping
A set of 96 PCR-based simple sequence length poly-
morphism (SSLP) markers from the Whitehead Institute
Center for Genome Research (Dietrich et al., 1995) spaced
at 20-cm intervals throughout the genome was used for
linkage analysis. Polymorphisms were distinguished via
polyacrylamide gel electrophoresis using an ABI 377
(Perkin-Elmer, Boston, MA). Additional chromosome 2
SSLP markers derived at the Whitehead Institute (www.
genome.wi.mit.edu) were used for fine scale mapping.
Testing regions of the shru interval using Celera’s draft
sequence also identified single nucleotide polymorphisms
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corresponding author. Two physical maps of the shru
interval were constructed. One used a PCR-based assay
on a mouse–hamster radiation hybrid mapping panel
(Research Genetics, Huntsville, AL). A 5-fold coverage
BAC contig was created by screening the library RPCI-23
(ResGen) and walking from marker D2Mit435 to
D2Mit183. Both of these physical maps were used to
confirm the accuracy of public and private draft DNA
sequences of the shru interval.
Genotyping
Genotyping of shru carrier mice and mutant embryos
was accomplished using PCR analysis of two SSLP markers
that flank the shrunken-head locus. D2Mit37 resides 1.1 cm
proximal and D2Mit159 lies 0.7 cm distal to the mutation.
Polymorphisms between alleles on the mutant BTBR strain
and wild-type C57Bl/6J or Cast/Ei strains were distin-
guished using 3.5% agarose gel electrophoresis.
Computational analysis of the shru genomic interval
Annotation of the shru genomic interval began with
Celera’s prediction of exons. BLAST analysis revealed that
all predicted exons in the interval had previously been
attributed to orthologous exons from human Titin tran-
scripts (Bang et al., 2001). The shru genomic interval was
also analyzed using the following gene prediction pro-
grams: GeneMarkTM (Georgia Institute of Technology),
Perceval (Oak Ridge National Laboratory), and Genotator
(University of Washington). None of the programs pre-
dicted coding sequences that were not previously ascribed
as part of Titin. BLAST analysis of the 177-kb shru
interval revealed no indication of any part of a gene other
than Titin. The GenBank entry AL928789 contains se-
quence data for a BAC (RP23-435F21) from the contig
that spans most of the interval. Analysis of these sequence
data confirmed the continuity of Celera’s draft sequence
and was used to fill in three small sequence gaps in the
shru interval.
Cell death assay
For whole-mount detection of cell death, 8.75 DPC
embryos were first dissected, then rinsed in Pannett and
Compton’s saline (PCS), and incubated in Nile Blue A
sulfate salt (0.2 mg/ml) in PCS for 20 min at 37jC. The
embryos were then destained in PCS until the background
clarified. Images were taken immediately using a Leica
M420 microscope and NIH Image 1.62 software.
RT-PCR
Total RNA (1 Ag) from 12 to 13 somites embryos was
reverse transcribed using random hexamer primers (Invitro-gen, Carlsbad, CA) and SuperScriptII RT (Invitrogen) at
25jC for 10 min and then 42jC for 50 min. PCR was
carried out using these primer pairs:
h-actin: 5V CTGTATGCCTCTGGTCGTAC, 5V GGATG-
TCAACGTCACACTTC
Titin: 5V TTCCAGAGTCATCACGGGTA, 5V GAGTAC-
CAGTTCCGTCTCAA
VEGF-A: 5VAGTGGTCCCAGGCTGCACC, 5V GTCTT-
TCTTTGGTCTGCATTCA
The following number of PCR cycles were used for Fig.
7A (h-actin, 19 cycles. Titin, 24 cycles. VEGF-A, 27
cycles). Each PCR was also performed using both fewer
and additional cycles to confirm that expression was being
assayed within the pseudo-linear phase of amplification.
LacZ histochemistry and histological analysis
h-galactosidase activity was detected in flt-shru embryos
following the protocol of Hogan et al. (1994). Embryos
were dehydrated in an ethanol series, embedded in Paraplast
Plus paraffin (Fisher), and sectioned at 10 Am. For histo-
logical analysis, 10-Am paraffin sections were stained with
Lee’s methylene blue-basic fuchsin dyes (Bennett et al.,
1976).
Antibody staining and endothelial cell quantification
Immunofluorescence and whole-mount immunohisto-
chemistry were performed using a primary antibody directed
against the endothelial marker PECAM-1 (MEC13.3, rat
anti-mouse monoclonal, Pharmingen). For fluorescence
staining, 10-Am cryostat sections were incubated with
MEC13.3 (1:60 dilution). AlexaFluor488-conjugated goat
anti-rat secondary antibodies (1:500 dilution, Molecular
Probes) were used to detect MEC13.3 localization. The
DNA-binding dye Hoechst 2258 (0.4 mg/ml) was used to
stain nuclei. Slides were then analyzed using a Leica DMRB
microscope and Spot32 (Diagnostic Instruments, Inc.) im-
aging software. Whole-mount immunostaining of embryos
with MEC13.3 (1:110 dilution) was performed as described
(Suri et al., 1996) using the Vectastain ABC developing kit
(Vector Laboratories).
For the EC quantification, every third 10-Am section
from level of the cardiac inflow tract to the yolk sac vascular
connection was collected. PECAM-1 and Hoechst staining
identified individual ECs comprising the dorsal aortae.Results
Identification of shrunken-head
The shrunken-head mutant was isolated in a genetic
screen designed to identify recessive mutations that produce
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with ethyl-nitroso-urea (ENU) and bred to create a founding
population of mice harboring random germ-line mutations.
The resulting G0 males were backcrossed for two gener-
ations to C57Bl/6J females. Dissecting the litters from G2
females mated with their G1 father at 10.5 DPC allowed
individual lines of mice to be assayed for recessive devel-
opmental phenotypes (Hentges et al., 1999). One of the
mutations, shrunken-head, produces a phenotype that
includes reduced growth of the head, a defective cardiovas-
cular system, and regionally restricted increases in cell
death.
Mapping of the shrunken-head gene
To facilitate identification of carrier animals and mutant
embryos by genotyping and to allow candidates for the
shru locus to be evaluated, the mutation was meiotically
mapped. Initially, linkage to the middle of chromosome 2
was established using DNA from 12 known heterozygous
shru carriers. Genotyping and testing of additional animals
indicated that the mutation was fully penetrant on different
genetic backgrounds. This allowed high-resolution map-
ping to proceed. To utilize a higher degree of polymor-
phism for the mapping process, shru was crossed from
Mus musculus domesticus onto a more distantly related
subspecies of mouse, Mus musculus castaneus. Over
10,000 meioses were scored using additional chromosome
2 markers, leading to a non-recombinant interval contain-
ing the shrunken-head locus that spans 177 kb of genomic
sequence (Fig. 1A).
The shru mutation resides within the gene for Titin
The availability of draft sequence of the mouse ge-
nome from both the public sequencing effort and Celera
greatly aided mapping of the shru locus. Genetic mapping
information was rapidly correlated with a detailed physical
map provided from Celera’s draft sequence. The continu-
ity and orientation of Celera’s draft sequence covering the
shru interval were confirmed through haplotype analysis
of shru recombinants, by creating a BAC contig of the
interval, and by analyzing marker loci using a mouse–
hamster radiation hybrid mapping panel (data not shown).
The mouse BAC RP23-435F21 contains DNA covering
most of the shru interval and was sequenced by the
Wellcome Trust Sanger Institute. Analysis of this se-
quence also confirmed the size and continuity of the shru
interval.
The 177-kb non-recombinant interval was found to
reside within the 3V portion of the Titin gene (Fig. 1B).
The Titin locus produces giant filamentous proteins
expressed in cardiac and skeletal muscle. Titin filaments
have been demonstrated to serve as structural components
within muscle fibers, providing an extensible scaffold for
the contractile machinery. Titins are required for elasticityas well as structural integrity of muscle fibers. Extensive
computational analysis of this interval has yielded 272
predicted exons, all of which have been ascribed to at least
one of Titin’s many transcripts. We therefore conclude that
disruption of Titin function produces the shru phenotype.
Levels of Titin mRNA expression remained unchanged in
shru mutants (Fig. 7A). During mid-gestation of the
mouse, Titin is expressed in the myocardium of the heart
and in the somites (Schaart et al., 1989). Titin’s mRNA
expression pattern was unchanged in mutants (data not
shown). Loss of Titin function in shru results in cardiac
failure followed by defective vascular morphogenesis and
increased mesenchymal cell death.
Titin regulates cardiomyocyte shape and alignment
Mutations in Titin are known to cause dilated cardiomy-
opathy in humans and zebrafish (Gerull et al., 2002; Xu et
al., 2002). Shru hearts are weakly contractile from the
outset, develop pericardial edema by 9.5 DPC, and progres-
sively fail. Mutant hearts appeared normal at 8.25 DPC
(data not shown). Shortly after the first visual appearance of
cardiac defects, mutant embryos were sectioned at 8.75
DPC and histologically stained to examine heart morphol-
ogy (Fig. 2). Overall, shru hearts appeared neither dilated
nor hypertrophic. Cells of both the myocardium and endo-
cardium normally align smoothly to create a single cell layer
of each tissue, separated by deposited ECM called cardiac
jelly. Individual cardiomyocytes in shru hearts did not
become distended as occurs with mutation in zebrafish
Titin. In addition, the number and extent of trabecular
projections from the myocardium into the cardiac jelly were
reduced in the mutants, indicating defective endocardial and
myocardial cellular interaction. Despite its poor contractility
and lack of circulation, shru hearts underwent normal
cardiac looping morphogenesis and proper regionalization
as assayed by dHAND and eHAND expression (data not
shown).
Developmental defects outside of the heart
Shrunken-head embryos exhibited a variety of develop-
mental defects both within and outside of Titin’s expression
domain (Fig. 3). Shru embryos could first be distinguished
from their wild-type littermates at 8.5 days of gestation
based on the exterior appearance of the heart. During the
subsequent 24 hours of development, an overall reduction in
growth, most prominent in the head, was seen. Immediately
following the normal onset of cardiac contractions, 8.75
DPC shru embryos showed apparent necrosis in the fronto-
nasal mesenchyme. By 9.0 DPC, the mandibular component
of the first branchial arch, the region of head mesenchyme in
apposition to the forebrain neurectoderm, and the interior of
the somites (the scleratomal precursor region) became
hollow, indicating a loss of particular cell types (Figs. 3E
and F; and data not shown).
Fig. 1. Genetic mapping of the shrunken-head mutation within the Titin gene. (A) Shru was meiotically mapped to the long arm of chromosome 2 in a region
that is homologous to human chromosome 2q31. Markers D2Gal4 and D2Gal11 define a non-recombinant genetic interval that is 177 kb. This interval resides
within the gene for Titin (Ttn). (B) D2Gal4 lies in the 3V UTR of Titin. D2Gal11 lies in between Titin exons 91 and 92. This section of the locus resides within
the I-band region of Titin, encoding the carboxy portion of the proximal tandem Ig segment. This annotation depicts the layout of Titin filaments within the
half-sarcomere, Titin’s known protein interaction domains and Titin’s own domain structure.
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of mutant embryos could result from cell death, inappro-
priate cell-type specification, decreases in proliferation, or
aberrant cell migration. To investigate the idea that cell
death was the cause, we used the vital dye Nile Blue
Sulfate. Embryos (8.75 DPC) were stained and examined
in whole-mount (Fig. 4). Wild-type embryos exhibited a
scattered staining pattern with higher levels in structures
such as the otic vesicles and rhombencephalic roof. Mutant
embryos had staining in addition to that seen in wild-type
embryos. The elevated staining pattern in mutants at 8.75
DPC was entirely consistent with the pattern of later cellloss. Increased staining levels were seen in the somites
(Fig. 4D) and in the mesenchyme of the frontonasal mass
and of the first branchial arch (Fig. 4B). Localized
increases in cell death therefore account for the absence
of these particular cell populations in shrunken-head
mutants.
Defects in the function and architecture of the vascular
system were readily apparent in shru embryos. Weakly
contractile shru hearts failed to initiate embryonic circula-
tion (Figs. 3A, D, and G). Once circulation did begin after
9.5 DPC, local areas of hemorrhage, prominent in the head,
branchial arches, and limb buds, were present throughout
Fig. 2. Weakly contractile shru hearts had misaligned and abnormally shaped cardiomyocytes. When contrasted to wild-type (wt) (A), the shru heart (B) had a
crinkled exterior appearance at 9.5 DPC. Sectioning of 8.75 DPC embryos revealed there are fewer trabeculae (green arrowheads) in mutant (D) than in wt (C)
hearts. The red arrowhead in D indicates an abnormal clump of trabecular cells. Mutant myocardial and endocardial cells were misaligned with each other.
Mutant cardiomyocytes had a cuboidal shape instead of the wild-type spindle shape.
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embryos indicated defective vascular development (Fig.
3H). The shrunken-head mutation causes lethality by 11.5
DPC, most likely because of the progression of these
cardiovascular defects. Considering that the blood vessel
defects and most of the increased cell death occur outside of
Titin’s striated muscle expression, these components of the
shru phenotype are likely to be a secondary result of cardiac
dysfunction. It is noteworthy that shru embryos exhibit little
variability in any aspect of their phenotype, indicating that
absent circulation results in a specific and reproducible
developmental deficit.
Regulation of angiogenesis is defective in shrunken-head
embryos
The delayed onset of circulation in shru mutants pro-
vided the opportunity for a detailed investigation into therole of blood flow in vessel development. We first exam-
ined the extraembryonic vascular system in mutant em-
bryos. Formation of the yolk sac vasculature involves both
vasculogenesis and angiogenesis. An initial primitive vas-
cular network of homogeneously sized vessels has been
formed by 8.5 DPC via vasculogenic mechanisms. In wild-
type embryos, angiogenic growth through sprouting and
splitting of existing vessels combined with pruning and
remodeling mechanisms had created a fractal network of
large vitelline vessels and interconnecting fine capillaries
by 9.5 DPC (Fig. 5A). Whole-mount and histological
analyses of mutant yolk sacs at 8.5 DPC revealed no
obvious abnormalities (data not shown). Angiogenesis
defects were readily apparent by 9.5 DPC in the yolk sacs
of shru embryos. Yolk sac blood vessels retained the
primary vascular plexus architecture indicating little, if
any, angiogenesis (Fig. 5B). This finding was confirmed
via whole-mount PECAM-1 immunostaining (data not
Fig. 3. Morphology of the shrunken-head phenotype. The first signs of the shru phenotype were apparent by 8.75 DPC (A–C). The optic vesicles were
compressed along the anterior–posterior axis (arrowhead in C) when contrasted with wild-type (B). By 9.0 DPC (D–F), mutant embryos were growth
retarded, but not developmentally delayed. At this stage, loss of cells in the frontonasal mesenchyme (arrowhead in E) and the first branchial arch (arrowhead
in F) was visible. By 9.5 DPC (G–I), shru heads were markedly reduced in size. The absence of red blood cells along the dorsal aorta (arrowheads in A, D,
and G) indicated vascular dysfunction in shru embryos. Mutants eventually developed hemorrhage (arrowheads in H) and progressively failing hearts (arrows
in C and I).
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cells in the vessels of the embryonic body axis. This
demonstrates that there must have been at least some
angiogenesis to connect the extraembryonic and embryonic
vascular beds, which develop separately. By 10.5 DPC,
shru yolk sacs appear avascular (data not shown), indicat-
ing that the extraembryonic blood vessels have been
retracted.
To gain more insight into which cellular processes of
angiogenesis are affected by the absence of blood flow, the
vascular system of the embryo was examined in whole-
mount from 8.8 to 9.2 DPC. Vessels were visualized using
immunohistochemical detection of an antibody directed
against the endothelial marker PECAM-1. The intersomitic
vessels are some of the first embryonic vessels to form
primarily by angiogenesis. ECs from the dorsal aortae
project plasma membrane sprouts dorsally between the
somites. These sprouting ECs then migrate towards the
developing cardinal vein eventually forming fine capillary
connections. The initial budding of intersomitic vessels
appeared to occur normally in mutant embryos. Soon after
these sprouts arose, they formed into abnormally dilated
vessels (Fig. 5F).Analysis of the vascular architecture at 9.0 DPC revealed
other defects in angiogenesis. The dilated intersomitic
vessels sprouted into aberrant locations, such as across or
into somites (Fig. 5G). This resulted in abnormal connec-
tions between neighboring vessels. In addition, intersomitic
capillaries later regressed completely, indicating excessive
vascular pruning (Fig. 5H). Because the somites of shru
mutants displayed increased cell death by 8.75 DPC, these
intersomitic vessel defects could be attributed to loss of
circulation, somitic cell death, or both. In other locations
such as the head, the vasculature retained the primitive
honeycomb pattern formed during vasculogenesis. There
appeared to be minimal angiogenic growth, a lack of
vascular remodeling, and possibly increased vessel fusion
in the head (Fig. 5D).
Lack of circulation leads to abnormal endothelial shape,
cell–cell contacts and cellular distribution
Local areas of hemorrhage developed in shru embryos
once the delayed circulation began after 9.5 DPC. The
failure of vessel integrity at 9.5 DPC as well as the
widespread abnormalities in angiogenesis led us to specu-
Fig. 4. Increased cell death preceded the loss of mesenchyme. Nile Blue Sulfate staining of 8.75 DPC embryos revealed increased cell death in shru mutants (B
and D). Punctate blue staining marked normal areas (green arrowheads) of cell death such as the rhombencephalic roof and otic vesicles during development of
wild-type embryos (A and C). Mutants had increased staining in the mesenchyme of the frontonasal mass and first branchial arch (red arrowhead in B) as well
as in the somites (red arrowheads in D).
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maintenance and continued development of vasculogenic
vessels in the embryo. We addressed the effect of absent
circulation on the development of vasculogenic vessels by
examining the dorsal aortae of 8.7 DPC embryos (Fig. 6).
ECs comprising the dorsal aortae were identified in cross-
sections using an antibody directed against PECAM-1.
Quantification and visual analysis of these ECs revealed
several distinct defects of vascular morphogenesis. A
lumen was absent at many sites along the length of mutant
vessels (Fig. 6E), despite the presence of PECAM-labeled
ECs. In contrast, lumenal integrity was established
throughout the length of the dorsal aortae in wild-type
embryos. Sections in which mutant vessels lacked a clear
lumen seemed to be associated with fewer PECAM-labeled
ECs. This suggested either that ECs were mispositioned
along the axis of the vessel or that there was an overall
reduction in EC number. A comparison of the number of
dorsal aorta ECs from serial sections indicated that the
normal numbers of ECs were present in mutants (Fig. 7K).
There was wide variation in the width of the mutant dorsal
aortae in these sections. This abnormal width variation,
which was also visible in whole-mount PECAM-labeled
embryos (data not shown), seemed to occur randomly
along the entire vessels. The variance in EC number
between sections was significantly larger in mutant em-
bryos, indicating that individual ECs were actually mis-
positioned along the A–P axis of these vessels. Analysis
via whole-mount PECAM staining of the dorsal aortae asprimitive ECs had just coalesced into vascular cords at 8.0
DPC indicated that the distribution of ECs at this time was
normal (data not shown).
To search for a mechanistic cause(s) for these lumen
formation and EC-distribution defects, the structure of
mutant ECs in PECAM-labeled cross-sections was exam-
ined. The majority of embryonic cell types appeared to have
normal shapes in sections of mutants. However, many ECs
comprising the dorsal aortae in shru embryos had abnormal
profiles. In contrast to the flattened profile of squamous
wild-type ECs that have undergone spreading (Figs. 6A and
C), mutant ECs tended to have a more globular profile (Figs.
6B, D, and F). Abnormal cellular protrusions that extended
either apically or lumenally were visible in some mutant
ECs. Several observations also demonstrate that cell–cell
contacts were defective between mutant ECs. Wild-type
ECs within a vessel make contact with their neighbors only
along the edges of their flattened bodies. In contrast,
extensive areas of cell–cell contact were seen between
mutant ECs (Figs. 6E and F). The distribution of
PECAM-1 staining on shru ECs also suggested defective
cell – cell contact. In wild-type migrating angioblasts,
PECAM-1 is uniformly distributed over the surface of the
cell. Upon establishment of adheren junctions that lead up to
lumenal morphogenesis, PECAM-1 is redistributed to the
sites of contact (Fig. 6A and (Drake and Fleming, 2000)). In
mutant ECs, PECAM-1 had a relatively widespread distri-
bution, with limited concentration at areas of cell–cell
apposition (Figs. 6B, E, and F).
Fig. 5. Shru angiogenesis was limited and misregulated. By 9.5 DPC, angiogenesis had remodeled the wild-type (A) yolk sac vasculature into large and small
caliber vessels. A mutant yolk sac at 9.5 DPC (B) retained the primitive vascular plexus pattern of homogeneously sized, large-bore vessels created during
vasculogenesis. PECAM staining (C–H) revealed a more complex vascular network created by angiogenic sprouting and remodeling in a 9.0 DPC wt head (C).
A 9.0 DPC shru head (D) showed dilated blood vessels with little sign of angiogenesis. At 8.8 DPC, angiogenic sprouting of the intersomitic vessels appeared
relatively equivalent when comparing wt (E) and mutant (F) embryos (compare green arrowheads). The red arrowhead in F indicates an abnormally dilated
vessel in the mutant. At 9.0 DPC in the mutant (G), PECAM-stained cells appear to extend abnormally into and around the somites (red arrowheads)
originating from intersomitic vessels and the cardinal vein. Widespread vessel regression in the mutant at 9.2 DPC (H) resulted in the retraction of proper
intersomitic vessels, but the aberrant somatic PECAM-stained cells remained.
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phenotype
VEGF is a critical regulator of vascular morphogen-
esis. Several of the vascular defects seen in shru mutants
such as the abnormal positioning and profiles of dorsal
aortae ECs and increased vessel diameter resemble the
effects of elevated VEGF signaling. VEGF expression is
also known to be upregulated in response to hypoxia
(Shweiki et al., 1992). The lack of circulation in shru
mutants exposes embryos to the effects of hypoxia.
Based on this, we investigated the role of VEGF in
contributing to the defective vascular morphogenesis seen
in shru mutants. Quantitative RT-PCR results indicated
that VEGF-A expression was upregulated approximately
1.5- to 1.7-fold in shru mutants at 8.7 DPC (Fig. 7A).
Assaying global mRNA expression using Affymetrix
gene chips confirmed this result as VEGF expression
was elevated 1.5-fold in 8.7 DPC mutants (data not
shown).
Although VEGF is an extremely potent regulator of
vascular development, the increased VEGF expression seen
in shru mutants at 8.7 DPC was somewhat modest. We
chose a genetic approach to determine if this elevated VEGF
expression in shru mutants could be capable of affecting
vascular development in vivo. We crossed a null allele of
Flt-1 (a receptor for VEGF) onto the shrunken-head mutant
background. Flt-1 is thought to serve an inhibitory role in
VEGF signaling. Reduction of Flt-1 function would likely
exacerbate any affects that elevated VEGF signaling was
having on the endothelial cell defects in shru.
The null allele of Flt-1 used (Flt-1 LacZ) was created by
replacing part of its coding sequence with that of the LacZ
gene (Fong et al., 1995), providing a useful histochemical
marker for the endothelium. Examination of the vasculatureFig. 6. Defective endothelial shape, cell –cell contacts, and mispositioning
of ECs in shrunken-head mutants. PECAM-1 immunofluorescence (green)
and Hoechst staining of nuclei (blue) from 10-Am transverse sections were
used to visualize a cross-section of right dorsal aorta from 12-somite
embryos (panels A–F). In a wild-type embryo (A), the lumen of the dorsal
aorta was filled with cylindrical red blood cells (marked with *). In panel C,
a wild-type endothelial cell has been shaded red to illustrate the thin profile
typical to the simple squamous epithelium of a vessel. Many mutant ECs
(B, D, and F) possessed a thick profile. A shru EC shaded in red (D) had
abnormal apical and lumenal plasma membrane protrusions. Aberrant
cellular profiles and lumenal plasma membrane protrusions in shru mutant
ECs are also shown in F (red arrowheads). Mutant ECs in the dorsal aorta
(E) also displayed defective cell –cell contacts, making contact with each
other along large extents of their cell surfaces. The failure of PECAM-1
staining to be redistributed to sites of cell contact (yellow arrowheads in E
and F) is consistent with defective cell –cell contacts in mutant ECs. A clear
vascular lumen was absent in many mutant sections (E). ECs exhibited a
scattered distribution along the anterior–posterior axis in shru mutants.
Scatter plots show the number of ECs forming each side of the dorsal aorta
per section in wt and shru (G). The mean number of ECs between wt and
mutant did not differ significantly (see Fig. 7K), but the variance (s2) was
substantially higher in shru (s2: 15.60) than wt (s2: 2.60), indicating cells
were mispositioned.
Fig. 7. Increased VEGF signaling likely contributes to vascular defects in shru. (A) Quantitative RT-PCR indicated elevated VEGF-A expression in shru
mutants at 8.75 DPC. The shrunken-head mutation also genetically interacted with Flt-1 to regulate EC number (B–K). A flt-shru mutant showed much
stronger staining of the Flt-1 LacZ knock-in reporter than wt at 8.75 DPC (B). Transverse sections of these LacZ-stained embryos revealed elevated numbers of
Flt-1-expressing cells scattered throughout the mesenchyme of the flt-shru mutant (D and F) compared to the wild-type vasculature of the flt-1+/ embryo (C
and E). Vasculogenic vessels in flt-shru mutants had abnormally large lumens with ectopic clusters of Flt-1-expressing cells inside the lumens. PECAM-1
staining in the dorsal aortae was used to quantitate the increased number of ECs in flt-shru embryos. Transverse sections from 11 to 13 somite embryos were
immunofluorescently labeled using a PECAM-1 antibody (green). Nuclei (blue) were counterstained with Hoechst. Wild-type (G) and shru/ (H) showed
similar numbers of ECs. Sections from a flt-shru mutant (I) and a flt-1/ mutant (J) revealed an increase in EC number. The number of ECs comprising a 10-
Am section of dorsal aorta is shown in K. The mean number of ECs does not differ significantly between wild-type and shru (bars indicate SEM). The increase
in ECs seen in flt-shru mutants is significant (P < 0.05), but not as large as the increase of ECs in flt-1/ mutants. Flt-1 LacZ staining appeared equivalent in a
wt (L) and a flt-shru mutant (M) at 7.4 DPC, indicating similar numbers of angioblasts. However, a flt-1/ mutant (O) had a clear increase in angioblast
number compared to wt (N) at 7.5 DPC.
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interaction in 8.75 DPC embryos heterozygous for Flt-1
LacZ and homozygous for shru (called flt-shru embryos
hereafter). Whole-mount staining for h-gal in flt-shru em-
bryos at 8.75 DPC showed an excess of flt-1-expressing cells
and vascular disorganization throughout flt-shru embryos
(Fig. 7B). Embryos heterozygous for the Flt-1 mutation
possess a wild-type vasculature with no detectable increase
in EC number compared to wild-type embryos (Figs. 7C and
E and Fong et al., 1999). Sections of flt-shru mutants showed
increased numbers of Flt-1-expressing cells comprising
major vessels such as the dorsal aortae and the anterior
cardinal veins (Figs. 7D and F). These vessels had enlarged
lumens and ectopic Flt-1-expressing cells within the lumen.
Abnormal clusters of labeled cells were also scattered
throughout the mesenchyme. These characteristics of flt-
shru mutants appeared identical to that reported for Flt-1
homozygotes (Fong et al., 1995).
The presence of ectopic Flt-1-expressing cells in flt-
shru embryos raised the question of whether the flt-shru
phenotype indicated an overproduction of ECs or merely
aberrant Flt-1 expression. Ectopic cells within the lumens
of the dorsal aortae of flt-shru embryos were determined
to be PECAM-1-expressing ECs (Fig. 7I). A comparison
of EC number from these PECAM-labeled sections indi-
cated that flt-shru mutants have significantly more ECs
compared to shru/ or wt embryos, but this increase
was not as great as in Flt-1/ mutants (Fig. 7K). This
genetic interaction between Flt-1 and shru indicates that
the elevated VEGF expression characterized here can
affect blood vessel development in vivo and likely
contributes to the endothelial defects seen in shru
mutants.
The developmental basis for the vascular defects in flt-1
homozygotes has been traced back to an excessive number
of endothelial precursors at 7.0 DPC (Fong et al., 1999).
However, there was no detectable difference in the number
of ECs and precursors in flt-shru embryos versus Flt-1
heterozygotes when assayed between 7.4 and 8.25 DPC
(Figs. 7L and M and data not shown). The increase in the
EC population in flt-shru mutants is detectable at 8.5 DPC
(data not shown). This genetic interaction reveals a new role
for Flt-1 in regulating EC number after lumenization of
blood vessels.Discussion
The shrunken-head mutation produces a complex set of
developmental malformations, including cardiovascular def-
icits and increased death of specific cell types. Localization
of the shru mutation within the Titin gene has revealed new
roles for Titin in heart development and has yielded impor-
tant insights into the role of circulation in vascular morpho-
genesis and maintenance of particular mesenchymal cell
types.Titin controls the alignment and shape of cardiac cells
A large body of evidence exists supporting structural
roles for Titin filaments in cardiac and skeletal muscles
(Gregorio et al., 1999). The Titin locus encodes single
polypeptides that can be over 3 MDa which are quite
modular in structure. Single Titin polypeptides have been
shown to span half the sarcomere from the Z-disc to the M-
line. Titins are believed serve as blueprints for sarcomere
assembly; aligning other structural, regulatory, and contrac-
tile proteins within the sarcomere via direct protein–protein
interactions. In this manner, Titin coordinates the precisely
arranged assembly of myofibrils into more complex sarco-
meric structures in striated muscle (van der Ven et al., 2000).
By serving as a molecular spring, Titin has also been shown
to maintain the structural integrity of contracting myofibrils.
These spring-like features of Titin polypeptides provide
muscle fibers with passive elasticity (Labeit and Kolmerer,
1995; Linke et al., 2002). The Titin locus is subject to
complex transcriptional regulation and alternative splicing.
The use of alternative 3V termini and the inclusion or
exclusion of particular exons produce diverse Titin products
with different myofibril assembly and elasticity properties
(Bang et al., 2001; Freiburg et al., 2000). Considering
Titin’s structural roles in striated muscle, it is not surprising
that the shru mutation produces an embryonic lethal car-
diovascular phenotype. The nature of this phenotype reveals
new roles for Titin in regulating the alignment and shape of
developing cardiomyocytes.
The shru mutation produces poor contractility of the
embryonic heart and delays the onset of circulation by more
than a day. Despite this lack of circulation, cardiac mor-
phogenesis and the pattern formation are not affected in
shru mutants, indicating that proper heart function is not
required for these developmental processes. Shru hearts are
weakly contractile from the outset, indicating that at least
some elements of the cardiac contractile apparatus are
assembled. In the mouse heart, Titin expression begins at
7.75 DPC, preceding myofibril assembly. Mutations in Titin
have been shown to cause dilated cardiomyopathy in
humans, zebrafish, and the mouse (Gerull et al., 2002;
Gotthardt et al., 2003; Xu et al., 2002). In the zebrafish
mutant pikm171, loss of Titin function in the heart reduces
the number of myofibrils and severely limits contractility of
the heart. In addition, loss of muscle elasticity can be seen in
individual cardiomyocytes as they become thin and bulge
outwards after contraction has begun. Shru hearts do not
possess a dilated cardiomyopathy phenotype. Instead, cells
in the myocardium and endocardium are cuboidal and
misaligned. The aberrant cuboidal shape seen in shru
cardiomyocytes could result from problems in myofibril
assembly or a defective cytoskeleton. Interestingly, the
cellular defects in shru hearts closely resemble those seen
in hearts null for Mef2c (Bi et al., 1999) or N-cadherin (Luo
et al., 2001; Radice et al., 1997). The fact that myocardial
cells that form trabeculae are also misaligned makes it less
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defects seen in shru hearts. Given the differences between
shru hearts and those with previously documented Titin
mutations, it seems likely that shru is a hypomorphic allele
that does not abolish muscle elasticity. This could explain
why shru cardiomyocytes do not appear to stretch out
excessively as in zebrafish pickwick mutants. The shru
mutation does not alter Titin’s mRNA expression pattern
or levels. Because shru was induced by ENU, it is most
likely a point mutation distal to the N2B region of I-band
Titin that either creates a nonsense or missense codon, or
alters a splice donor or acceptor site.
Titin and cell death
In addition to those mutations that cause dilated cardio-
myopathy, other documented mutations in mouse and hu-
man Titin cause muscular dystrophy in the adult (Garvey et
al., 2002; Hackman et al., 2002). This progressive break-
down and loss of certain skeletal muscle tissue is thought to
result from sarcomeric instability. However, none of the
other Titin mutations have been shown to cause cell death in
the developing somites, the precursors to skeletal muscle
and bone. Shru embryos display distinct areas of increased
cell death at 8.75 DPC, including the sclerotomal precursor
regions of the somites. Titin expression begins in the
somites at 8.25 DPC even though skeletal muscle contrac-
tions do not begin until many days later in gestation.
Elevated cell death within mutant somites could indicate a
local role for Titin in preventing cell death or could be a
secondary result of the cardiac defects.
Complete circulatory insufficiency appears to cause
widespread death from hypoxia in virtually all cell types
at 9.5 DPC. Shru embryos have increased levels of cell
death in specific cell populations of the head evident at 8.75
DPC. These regions, the frontonasal mass and the first
branchial arch, are all comprised of mesenchymal cell types.
Because these areas of the embryo do not express Titin, we
believe this specific pattern of cell death is the result of
cardiac dysfunction. Mutations in the BMP signaling medi-
ator Smad5, the GTPase-activating protein p120-rasGAP,
and the serine–threonine kinase Lkb1 produce a similar
pattern of cell death coincident with apparent cardiac
dysfunction (Henkemeyer et al., 1995; Yang et al., 1999;
Ylikorkala et al., 2001). However, these mutations produce
a variety of developmental defects so it is difficult to assess
the role of cardiovascular function in maintaining these
cells. A null mutation in Ncx1 produces embryos that lack
a heartbeat and embryonic blood circulation (Koushik et al.,
2001). Ncx1 is a sodium–calcium exchanger expressed
exclusively in the heart up to 11.0 DPC. Defects seen in
these embryos outside of the heart are believed to result
from lack of cardiac function. The first branchial arch of 9.5
DPC Ncx1/ mice is hollow and hypoplastic, indicating a
loss of this cell population (Conway et al., 2003). This
closely resembles the pharyngeal arch in shru embryos. Thefrontonasal region of Ncx1/ mice has not been examined
closely to determine if it also exhibits the cell death pattern
that characterizes shru embryos. We believe that cells in the
first branchial arch and frontonasal mesenchyme die pre-
maturely in shru embryos because they are either more
affected by hypoxia than other tissues or that cardiovascular
failure produces aberrant signaling leading to increased
apoptosis. The head mesenchyme of wild-type embryos
shows evidence of hypoxia by 8.5 DPC (Lee et al., 2001).
This could indicate why these cells appear to be some of the
first to die after failure to establish embryonic circulation.
Biomechanical forces direct vascular morphogenesis
Shrunken-head embryos display various morphogenic
defects during vessel development. In the yolk sac, vasculo-
genesis appears to occur normally, but the resulting primi-
tive vascular network does not undergo angiogenic
remodeling. In the embryo itself, angiogenesis is reduced
and its spatial regulation is abnormal. Vessels within the
embryo do not maintain the integrity of vascular lumens. At
the cellular level, shrunken-head ECs have defects in their
shape, their position, and in interactions with their neigh-
boring cells. Because the primary effect of the shru mutation
is to disrupt Titin function and alter contractility of the heart,
this provides an opportunity to understand how the lack of
circulation affects the cellular and network aspects of
vascular morphogenesis.
Ordinarily, endothelial precursors migrate to the site of
vasculogenesis and interact with other endothelial cells
through cell–cell contacts to form the primary vascular
plexus. Continued interaction between endothelial cells
allows this plexus to coalesce into a set of tubes. During
the transition from migration to tubulogenesis, endothelial
cells undergo dramatic cell shape changes. Migrating cells
have relatively compact cell bodies with directionally ex-
tended cell processes leading the migration. As they interact
with their fellows to form the vasculature, they adopt a
squamous shape. Endothelial precursors are believed to
mediate the beginning stages of vasculogenesis through
biochemical regulation of their cellular behaviors. Contrac-
tion of the heart begins soon after the first vessels of the
primary vascular plexus have lumenized. As soon as heart
contractions begin, endothelial cells that are forming the
vasculature are subjected to new biomechanical stimuli from
circulation. These include hydrostatic pressures, fluid shear
stresses, and cyclic strains. We believe that the lack of
biomechanical stimuli from absent circulation produces
many of the specific vascular morphogenic defects seen in
shru endothelial cells. In this context, fluid biomechanical
forces produced from the very onset of cardiac contractions
are required to direct vascular morphogenesis and endothe-
lial differentiation in vivo.
A large body of evidence indicates that hemodynamic
forces profoundly influence the phenotype of ECs in vitro
(Topper and Gimbrone, 1999). ECs in culture show
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changes in gene transcription, cell shape alterations, direc-
tional migration, and various alterations in metabolic and
synthetic activities. Of interest in relation to the shru
phenotype, ECs exposed in culture to steady laminar shear
stresses reproducibly elongate and align their axes in the
direction of flow (Galbraith et al., 1998). Reorganization of
actin-containing stress fibers begins within minutes of
exposure to this form of stimulus (Birukov et al., 2002).
ECs also migrate away from the source of steady laminar
flow. While much progress has been made in defining how
biomechanical stimuli alter EC phenotype in vitro and
which cellular molecules transduce these effects, many of
these models have not been tested in vivo.
Dynamic responses of blood vessels to hemodynamic
forces have been demonstrated in studies of the yolk sac
vasculature. After experimentally altering the pathway of
blood flow, yolk sac vessels begin retraction of superfluous
vessels and angiogenic growth and reorganization of new
vessels within minutes. It has become clear that circulation
is indeed required for angiogenesis within the yolk sac
(Koushik et al., 2001; Luo et al., 2001), and the study of
shru confirms that. Within the embryo, angiogenic growth
of some vessels follows a genetic program while others are
shaped primarily by the particular metabolic demands of
neighboring tissues (Graef et al., 2001). We demonstrate
that many of the cellular mechanisms of angiogenesis such
as sprouting and vessel interconnection and retraction are
preserved in the absence of circulation. However, an intact
circulation seems to be necessary to spatially direct these
cellular processes during vessel growth and reorganization.
In contrast to angiogenesis, vasculogenic development
begins before the onset of blood flow. Study of the bio-
chemical regulation of vasculogenesis has identified several
molecules that when mutated disrupt vasculogenic develop-
ment (for a review, see Sato, 1999). Vessels created during
vasculogenesis begin to exhibit defects after circulation has
been delayed in shru mutants. After the alignment of
primordial ECs at the vertices of future vessels and cell–
cell contact formation to create a lumen, shru ECs do not
assume the flattened, squamous shape typical of the endo-
thelial differentiation pathway. Instead, shru ECs retain
several characteristics resembling the more primitive state
of migrating angioblasts, such as noticeable plasma mem-
brane protrusions. This may indicate that shru ECs can lose
their apical–lumenal polarity acquired during vasculogene-
sis. Given the presence of these membrane protrusions
which angioblast use to migrate, we believe that shru ECs
comprising vessels migrate abnormally to create the uneven
distribution of cells seen along the vessel’s length. This
proposed migration defect coupled with abnormal cell–cell
contacts could lead to the disrupted lumenal integrity of
blood vessels in shru mutants. We conclude that biome-
chanical forces produced from circulation are required to
maintain vascular lumen integrity after vasculogenesis and
direct the functional phenotype of ECs by influencing theirshape and cell–cell contacts. The effects of hemodynamic
forces on ECs observed in vitro appear to be critical
components of early vessel morphogenesis in vivo.
Role of VEGF in shru mutants
VEGF is a critical regulator of several aspects of vascular
morphogenesis. VEGF regulates migration by functioning as
a chemoattractant for ECs. Increasing endogenous amounts
of VEGF results in increased vessel fusion and elevated
protrusive activity of EC plasma membranes (Drake and
Little, 1995; Drake et al., 2000). The vascular defects seen in
shru mutants resemble effects described from increasing
endogenous levels of VEGF, and indeed shru mutants have
increased expression of VEGF-A mRNA shortly following
the delay in circulation. Shru mutants eventually develop
dilated vessels in the head, and ECs possess abnormal
plasma membrane protrusions and an abnormal distribution
within vessels. A genetic interaction between the shru
mutation and a null mutation in Flt-1 produces an increase
in endothelial cell number in flt-shru embryos, thus reinforc-
ing that the increased VEGF expression at 8.7 DPC could
influence vascular development. Although significant, this
increase in EC number was not as large as that seen in Flt-
1/ mice. We interpret this relatively weak genetic inter-
action to result from elevated VEGF activity in shrumutants,
rather than as evidence that Titin and Flt-1 proteins might
physically interact. Given that expression of VEGF is
elevated in response to hypoxia, it is not surprising that
absent circulation in shru mutants would increase VEGF
levels. This is the earliest time point that VEGF activity has
been shown to be elevated following cardiac defects. Con-
sidering VEGF’s defined roles in vascular development, it is
possible that aspects of the shru vascular phenotype result
from altered VEGF signaling rather than from a response to
biomechanical stimuli. Interestingly, in zebrafish mutants
such as island beat which prevent blood circulation, VEGF
expression remains normal and early vascular development
proceeds unimpeded (Serluca et al., 2002). Although these
mutants lack vascular growth in some areas such as in the
kidney, ECs within vasculogenic vessels appear to form
normal cellular junctions.
The genetic interaction between Flt-1 and shru also
uncovered a new role for Flt-1 in regulating EC number.
It is clear from the timing of this interaction that Flt-1
continues to regulate EC number after lumenization of
blood vessels. It is not evident whether this is accomplished
by affecting EC proliferation or continued recruitment
mesodermal angioblasts.References
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